Drug
Bendamustine clinical trials
Also written Treanda, Ribomustin, SDX-105 and SyB L-0501.
- studies test it
- 237
- open now
- 24
- in phase 3
- 18
- first study started
- 2001
Keep track of what changes. Save the bendamustine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
236 studies that test it; most in 2010 (29)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 10 |
| 2009 | 28 |
| 2010 | 29 |
| 2011 | 22 |
| 2012 | 18 |
| 2013 | 15 |
| 2014 | 14 |
| 2015 | 14 |
| 2016 | 11 |
| 2017 | 11 |
| 2018 | 7 |
| 2019 | 3 |
| 2020 | 7 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 9 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 93
- Phase 2
- 166
- Phase 3
- 18
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 19
Who runs them
Industry 55 · Other 182
German CLL Study Group (10) · M.D. Anderson Cancer Center (9) · SymBio Pharmaceuticals (9) · Cephalon (8) · Hoffmann-La Roche (5) · Fondazione Italiana Linfomi - ETS (5) · Fred Hutchinson Cancer Center (5) · St. Petersburg State Pavlov Medical University (4)
Often tested with
Tested in the same studies.
Rituximab (83) · Dexamethasone (19) · Obinutuzumab (16) · Lenalidomide (15) · Bortezomib (14) · Ofatumumab (12) · Cyclophosphamide (11) · Fludarabine (11)
Studies
Open first, then newest update. How each study uses bendamustine is read from its arms, and is right about nine times in ten.
Testing it · 237
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT05139017Written as Bendamustine
- T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon CancerRecruitingPhase 1Fred Hutchinson Cancer CenterNCT06043713Written as Bendamustine
- Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.RecruitingPhase 2Swiss Cancer InstituteNCT07593482Written as bendamustine hydrochloride
- Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMRecruitingPhase 2Massachusetts General HospitalNCT06561347Written as Bendamustine
- Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaNot yet recruitingPhase 1Weill Medical College of Cornell UniversityNCT07725406Written as Lymphodepleting chemotherapy: Bendamustine
- Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular LymphomaRecruitingPhase 2University of California, DavisNCT04587687Written as Bendamustine Hydrochloride
- Study of Pembrolizumab With Bendamustine in Hodgkin LymphomaRecruitingPhase 2University Health Network, TorontoNCT04510636Written as Bendamustine Hydrochloride
- Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT07225985Written as Bendamustine
- BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaRecruitingPhase 2Christine RyanNCT06854003Written as Bendamustine
- Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT AssessmentNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07206264Written as Bendamustine + anti-CD20 monoclonal antibody/orelabrutinib + anti-CD20 monoclonal antibody
- Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström MacroglobulinemiaNot yet recruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT07169565Written as Bendamustine
- Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center StudyNot yet recruitingPhase 2The First Hospital of Jilin UniversityNCT07003464Written as Bendamustine
- Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3ANot yet recruitingPhase 2Sun Yat-sen UniversityNCT06961500Written as Bendamustine
- Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's MacroglobulinemiaNot yet recruitingNot applicablePeking Union Medical College HospitalNCT06942507Written as Bendamustine + Rituximab
- BV in the Treatment of Relapsed/refractory Hodgkin LymphomaNot yet recruitingPhase 4Xiuhua SunNCT06761911Written as Bendamustine
- MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin LymphomaNot yet recruitingPhase 2Fox Chase Cancer CenterNCT06557330Written as Bendamustine
- Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular LymphomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT06757894Written as Bendamustine
- Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05914662Written as Zanubrutinib, Bendamustine and Rituximab
- A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06554600Written as Bendamustine
- Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentRecruitingPhase 3Ruijin HospitalNCT06496308Written as Bendamustine
See all 237 studies that test bendamustine →
Given in every arm · 74 — bendamustine is usual care beside what is tested
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07634471Written as Bendamustine
- CD30 CAR for Relapsed/Refractory CD30+ T Cell LymphomaRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT04083495Written as Bendamustine
- Treatment of Participants With Primary or Secondary Progressive Multiple SclerosisRecruitingPhase 1/2Tr1X, Inc.NCT07477639Written as Bendamustine
- Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell TherapyNot yet recruitingPhase 1Saurabh DahiyaNCT07790575Written as Bendamustin
- Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell TransplantRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04022239Written as Bendamustine
- DALY II USA/ MB-CART2019.1 for DLBCLRecruitingPhase 2Miltenyi Biomedicine GmbHNCT04792489Written as Bendamustine
- CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingPhase 1Mayo ClinicNCT04892277Written as Bendamustine
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseaseRecruitingPhase 1Fate TherapeuticsNCT06308978Written as Bendamustine
- CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin LymphomaNot yet recruitingPhase 1New York Medical CollegeNCT07575893Written as Bendamustin
- MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian CancerRecruitingPhase 1Mayo ClinicNCT06483048Written as Bendamustine
- B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesRecruitingPhase 1Mayo ClinicNCT06191887Written as Bendamustine
- Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.RecruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT04223765Written as Bendamustine
- FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid TumorsRecruitingPhase 1Fate TherapeuticsNCT06241456Written as Bendamustine
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLRecruitingPhase 3InnoCare Pharma Inc.NCT06363994Written as Bendamustine Injection
- A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell LymphomaRecruitingPhase 2Ruijin HospitalNCT06136351Written as Bendamustin
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLActive, not recruitingPhase 3Acerta Pharma BVNCT02972840Written as Bendamustine
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)Active, not recruitingPhase 1/2GenmabNCT04663347Written as rituximab and bendamustine
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingPhase 2ECOG-ACRIN Cancer Research GroupNCT04115631Written as Bendamustine
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaActive, not recruitingPhase 3GenmabNCT06191744Written as Bendamustine
- A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaActive, not recruitingPhase 2CelgeneNCT06425302Written as Bendamustine
Showing 20 of 74.
As the comparator · 33 — what is tested is compared with bendamustine
- A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingPhase 3Hoffmann-La RocheNCT06084936Written as Bendamustine
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06091254Written as Bendamustine
- A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsRecruitingPhase 3BeOne MedicinesNCT06846671Written as Bendamustine
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Not yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07753369Written as Bendamustine Injection
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingPhase 3Ruijin HospitalNCT07719855Written as Bendamustine
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaRecruitingPhase 3The Lymphoma Academic Research OrganisationNCT06006117Written as Bendamustine
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)RecruitingPhase 3Dizal PharmaceuticalsNCT07139873Written as Bendamustine
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)RecruitingPhase 3CelgeneNCT06911502Written as Bendamustine
- Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyRecruitingPhase 2University of BirminghamNCT05848765Written as Bendamustine
- A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeRecruitingPhase 3SecuraBioNCT06522737Written as Bendamustine
- A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaRecruitingPhase 2Guangzhou Lupeng Pharmaceutical Company LTD.NCT07189065Written as Bendamustine
- Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07208981Written as Bendamustine + Rituximab
- A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin LymphomaNot yet recruitingPhase 3ImmuneOnco Biopharmaceuticals (Shanghai) Inc.NCT06465446Written as Bendamustine
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLActive, not recruitingPhase 3Acerta Pharma BVNCT02970318Written as Bendamustine
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT01886872Written as Bendamustine Hydrochloride
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisActive, not recruitingPhase 1/2Columbia UniversityNCT05451771Written as Bendamustine
- A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationActive, not recruitingPhase 3BeOne MedicinesNCT04002297Written as bendamustine
- A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingPhase 3Loxo Oncology, Inc.NCT05023980Written as Bendamustine
- Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5Active, not recruitingPhase 3The Lymphoma Academic Research OrganisationNCT06284122Written as Bendamustin
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)CompletedPhase 2Merck Sharp & Dohme LLCNCT05508867Written as bendamustine
Showing 20 of 33.
Codes
What other systems call bendamustine · ClinicalTrials.gg INT006589
- MeSH (NLM) D000069461Bendamustine HydrochlorideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9266D9P3PQBENDAMUSTINEConfirmed FDA, NLM, Wikidata
- RxNorm 134547Confirmed FDA, Wikidata
- Wikidata Q425745bendamustineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73261BendamustineOne source FDA
- DrugBank DB06769One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069461 | Bendamustine Hydrochloride | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9266D9P3PQ | BENDAMUSTINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 134547 | — | Confirmed FDA, Wikidata |
| Wikidata | Q425745 | bendamustine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73261 | Bendamustine | One source FDA |
| DrugBank | DB06769 | — | One source Wikidata |
Also registered as bendamustine hydrochloride (UNII 981Y8SX18M · RxNorm 1114693).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.